{"transactions":[{"id":769735,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T20:30:21.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":55150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":55150,"derivative":{"exercise_price":3.33,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":55150},"source":{"system":"sec-edgar","filing":"0001193125-26-232705","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000119312526232705/ownership.xml","form_type":"4"}},{"id":873730,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-02T21:30:19.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5,"value":25000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on February 27, 2026."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001193125-26-085510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000119312526085510/ownership.xml","form_type":"4"}},{"id":1052700,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-29T21:21:38.000Z","date":"2025-08-28","kind":"exercise","planned":false,"acquired":false,"shares":47040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On October 1, 2016, the reporting person was granted an option to purchase shares of Strongbridge Biopharma plc (\"Strongbridge\") which were assumed by Issuer in connection with the acquisition of Strongbridge. The options vested in full on October 5, 2021."}],"balance_after":0,"derivative":{"exercise_price":6.66,"expiration_date":"2026-10-01","underlying":"Common Stock","underlying_shares":47040},"source":{"system":"sec-edgar","filing":"0001867096-25-000145","document":"wk-form4_1756502494.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000186709625000145/wk-form4_1756502494.xml","form_type":"4"}},{"id":1052699,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-29T21:21:38.000Z","date":"2025-08-28","kind":"sale","planned":false,"acquired":false,"shares":42232,"price":7.9209,"value":334515.4488,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.920 to $7.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":219188,"source":{"system":"sec-edgar","filing":"0001867096-25-000145","document":"wk-form4_1756502494.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000186709625000145/wk-form4_1756502494.xml","form_type":"4"}},{"id":1052698,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-29T21:21:38.000Z","date":"2025-08-28","kind":"exercise","planned":false,"acquired":true,"shares":47040,"price":6.66,"value":313286.4,"ownership":{"direct":true},"balance_after":261420,"source":{"system":"sec-edgar","filing":"0001867096-25-000145","document":"wk-form4_1756502494.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000186709625000145/wk-form4_1756502494.xml","form_type":"4"}},{"id":1122594,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-04T23:02:33.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders."}],"balance_after":214380,"source":{"system":"sec-edgar","filing":"0001867096-25-000110","document":"wk-form4_1749078146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000186709625000110/wk-form4_1749078146.xml","form_type":"4"}},{"id":1148955,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-14T20:34:08.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 13, 2026 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":1.875,"expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-25-009380","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000106299325009380/form4.xml","form_type":"4"}},{"id":1489679,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T20:19:20.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 5, 2025 or the date of the Company's next annual meeting of stockholders."}],"balance_after":164380,"source":{"system":"sec-edgar","filing":"0001867096-24-000108","document":"wk-form4_1717618752.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000186709624000108/wk-form4_1717618752.xml","form_type":"4"}},{"id":1496415,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T20:57:35.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 29, 2025 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":7.07,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-24-011570","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000106299324011570/form4.xml","form_type":"4"}},{"id":1543055,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-11T20:05:49.000Z","date":"2024-03-15","kind":"other","planned":false,"acquired":true,"shares":6502,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Keveyis Sales 2023 Milestone achieved resulting in the settlement of the related Contingent Value Right (\"CVR\") in shares of Xeris Biopharma Holdings, Inc. (the \"Company\")'s Common Stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on October 5, 2021, the effective time of the Merger (as defined below), pursuant to the transaction agreement dated as of May 24, 2021 by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), where HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge, and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The number of shares of Common Stock for the CVR is equal to the product (A) $0.25 divided by the volume weighted average price for the Company's Common Stock as reported by\nNasdaq for the ten (10) Trading Days immediately prior to October 5, 2021 and (B) the number of CVRs held by the holder as reflected on the CVR Register."}],"balance_after":114380,"source":{"system":"sec-edgar","filing":"0001867096-24-000043","document":"wk-form4_1712865937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000186709624000043/wk-form4_1712865937.xml","form_type":"4"}},{"id":1727486,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-29T21:09:05.000Z","date":"2023-11-27","kind":"purchase","planned":false,"acquired":true,"shares":5400,"price":1.87,"value":10098.0,"ownership":{"direct":false,"nature":"By: JEFFREY W SHERMAN LIVING TRUST U/A DTD 03/21/2001"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":5400,"source":{"system":"sec-edgar","filing":"0001867096-23-000154","document":"wk-form4_1701292127.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000186709623000154/wk-form4_1701292127.xml","form_type":"4"}},{"id":1763479,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9200,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a \"PSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"The Ordinary Shares subject to the PSUs vest on January 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F16","text":"The Ordinary Shares subject to the PSUs vest on January 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763478,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4599,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a \"PSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F15","text":"The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4599},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763477,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4599,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a \"PSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F15","text":"The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4599},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763476,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19044,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a \"PSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The Ordinary Shares subject to the PSUs vest on January 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F14","text":"The Ordinary Shares subject to the PSUs vest on January 5, 2025."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":19044},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763475,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11426,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a \"PSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The Ordinary Shares subject to the PSUs vest on January 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F14","text":"The Ordinary Shares subject to the PSUs vest on January 5, 2025."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":11426},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763474,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3809,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a \"PSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":3809},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763473,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27942,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a \"PSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The Ordinary Shares subject to the PSUs vest on January 5, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The Ordinary Shares subject to the PSUs vest on January 5, 2024."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":27942},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763472,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4654,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a \"PSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The Ordinary Shares subject to the PSUs vest on January 5, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The Ordinary Shares subject to the PSUs vest on January 5, 2024."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4654},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763471,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12226,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a \"PSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The Ordinary Shares subject to the PSUs vest on January 5, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The Ordinary Shares subject to the PSUs vest on January 5, 2024."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":12226},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763470,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18397,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs, (each, a \"RSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a \"Parent RSU\") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":18397},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763469,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12696,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs, (each, a \"RSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a \"Parent RSU\") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":12696},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763468,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9314,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs, (each, a \"RSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a \"Parent RSU\") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Ordinary Shares subject to the RSUs vest on January 5, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Ordinary Shares subject to the RSUs vest on January 5, 2024."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":9314},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763467,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":164469,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Option (as defined in footnote 5 to this Form 4) is fully vested."}],"balance_after":0,"derivative":{"exercise_price":22.14,"expiration_date":"2025-03-23","underlying":"Ordinary Shares","underlying_shares":164469},"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763466,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45352,"price":116.5,"value":5283508.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of ordinary shares of Horizon Therapeutics plc (\"Issuer\"), nominal value $0.0001 per share (\"Ordinary Shares\"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the \"Transaction Agreement\"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. (\"Parent\"), and Pillartree Limited, a wholly owned subsidiary of Parent (\"Acquirer Sub\"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the \"Scheme\") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the \"Effective Time\"), each outstanding Ordinary Share was converted into $116.50 in cash (the \"Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763465,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80944,"price":116.5,"value":9429976.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of ordinary shares of Horizon Therapeutics plc (\"Issuer\"), nominal value $0.0001 per share (\"Ordinary Shares\"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the \"Transaction Agreement\"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. (\"Parent\"), and Pillartree Limited, a wholly owned subsidiary of Parent (\"Acquirer Sub\"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the \"Scheme\") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the \"Effective Time\"), each outstanding Ordinary Share was converted into $116.50 in cash (the \"Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Ordinary Shares are held in the Jeffrey W. Sherman Living Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763464,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":105808,"price":116.5,"value":12326632.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of ordinary shares of Horizon Therapeutics plc (\"Issuer\"), nominal value $0.0001 per share (\"Ordinary Shares\"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the \"Transaction Agreement\"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. (\"Parent\"), and Pillartree Limited, a wholly owned subsidiary of Parent (\"Acquirer Sub\"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the \"Scheme\") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the \"Effective Time\"), each outstanding Ordinary Share was converted into $116.50 in cash (the \"Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held in the name of the Jeffrey W. Sherman 2020 Gift Trust, of which the reporting person's spouse is the Trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1763463,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-10-06T17:48:49.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2655,"price":116.5,"value":309307.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of ordinary shares of Horizon Therapeutics plc (\"Issuer\"), nominal value $0.0001 per share (\"Ordinary Shares\"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the \"Transaction Agreement\"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. (\"Parent\"), and Pillartree Limited, a wholly owned subsidiary of Parent (\"Acquirer Sub\"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the \"Scheme\") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the \"Effective Time\"), each outstanding Ordinary Share was converted into $116.50 in cash (the \"Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-052358","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052358/doc4.xml","form_type":"4"}},{"id":1764276,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-05T20:33:01.000Z","date":"2023-10-03","kind":"grant","planned":false,"acquired":true,"shares":16600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments over 36 months commencing on November 3, 2023, subject to the Reporting Person's continued service on the Board of Directors of the Company through each applicable vesting date."}],"balance_after":16600,"derivative":{"exercise_price":3.555,"expiration_date":"2033-10-03","underlying":"Common Stock","underlying_shares":16600},"source":{"system":"sec-edgar","filing":"0001062993-23-019067","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000106299323019067/form4.xml","form_type":"4"}},{"id":1785838,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-09-07T16:15:46.000Z","date":"2023-09-06","kind":"gift","planned":false,"acquired":false,"shares":2165,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held in the Jeffrey W. Sherman Living Trust."}],"balance_after":80944,"source":{"system":"sec-edgar","filing":"0001209191-23-048609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123048609/doc4.xml","form_type":"4"}},{"id":1863636,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-07T20:52:13.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 7, 2024 or the date of the Company's next annual meeting of stockholders."}],"balance_after":107878,"source":{"system":"sec-edgar","filing":"0001867096-23-000091","document":"wk-form4_1686171118.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000186709623000091/wk-form4_1686171118.xml","form_type":"4"}},{"id":2052429,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-18T16:21:49.000Z","date":"2023-01-17","kind":"gift","acquired":true,"shares":33795,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held in the Jeffrey W. Sherman Living Trust."}],"balance_after":83109,"source":{"system":"sec-edgar","filing":"0001209191-23-003738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123003738/doc4.xml","form_type":"4"}},{"id":2052428,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-18T16:21:49.000Z","date":"2023-01-17","kind":"gift","acquired":false,"shares":33795,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2376,"source":{"system":"sec-edgar","filing":"0001209191-23-003738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123003738/doc4.xml","form_type":"4"}},{"id":2055613,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-12T16:29:04.000Z","date":"2023-01-11","kind":"sale","acquired":false,"shares":3368,"price":113.1,"value":380920.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2022."}],"balance_after":36171,"source":{"system":"sec-edgar","filing":"0001209191-23-003146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123003146/doc4.xml","form_type":"4"}},{"id":2055612,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-12T16:29:04.000Z","date":"2023-01-10","kind":"sale","acquired":false,"shares":3368,"price":113.05,"value":380752.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2022."}],"balance_after":39539,"source":{"system":"sec-edgar","filing":"0001209191-23-003146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123003146/doc4.xml","form_type":"4"}},{"id":2060392,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units (PSUs)","published_at":"2023-01-06T17:54:54.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":9318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU/PSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The remaining ordinary shares subject to the PSU vest on January 5, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The remaining ordinary shares subject to the PSU vest on January 5, 2024."}],"balance_after":4654,"derivative":{"underlying":"Ordinary Shares","underlying_shares":9318},"source":{"system":"sec-edgar","filing":"0001209191-23-002439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123002439/doc4.xml","form_type":"4"}},{"id":2060391,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units (PSUs)","published_at":"2023-01-06T17:54:54.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":4834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU/PSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The ordinary shares subject to the PSUs vested on January 5, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The ordinary shares subject to the PSUs vested on January 5, 2023."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4834},"source":{"system":"sec-edgar","filing":"0001209191-23-002439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123002439/doc4.xml","form_type":"4"}},{"id":2060390,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units (PSUs)","published_at":"2023-01-06T17:54:54.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":1966,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU/PSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The ordinary shares subject to the PSUs vested on January 5, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The ordinary shares subject to the PSUs vested on January 5, 2023."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1966},"source":{"system":"sec-edgar","filing":"0001209191-23-002439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123002439/doc4.xml","form_type":"4"}},{"id":2060389,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units (PSUs)","published_at":"2023-01-06T17:54:54.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":7257,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU/PSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The ordinary shares subject to the PSUs vested on January 5, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The ordinary shares subject to the PSUs vested on January 5, 2023."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":7257},"source":{"system":"sec-edgar","filing":"0001209191-23-002439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123002439/doc4.xml","form_type":"4"}},{"id":2060388,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units (RSUs)","published_at":"2023-01-06T17:54:54.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":6348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU/PSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The remaining ordinary shares subject to the RSU vest ratably on January 5, 2024 and January 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The remaining ordinary shares subject to the RSU vest ratably on January 5, 2024 and January 5, 2025."}],"balance_after":12696,"derivative":{"underlying":"Ordinary Shares","underlying_shares":6348},"source":{"system":"sec-edgar","filing":"0001209191-23-002439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123002439/doc4.xml","form_type":"4"}},{"id":2060387,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units (RSUs)","published_at":"2023-01-06T17:54:54.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":9314,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU/PSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The remaining ordinary shares subject to the RSU vest on January 5, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The remaining ordinary shares subject to the RSU vest on January 5, 2024."}],"balance_after":9314,"derivative":{"underlying":"Ordinary Shares","underlying_shares":9314},"source":{"system":"sec-edgar","filing":"0001209191-23-002439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123002439/doc4.xml","form_type":"4"}},{"id":2060386,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units (RSUs)","published_at":"2023-01-06T17:54:54.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":12095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU/PSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The final tranche of ordinary shares subject to the RSU vested on January 5, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The final tranche of ordinary shares subject to the RSU vested on January 5, 2023."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":12095},"source":{"system":"sec-edgar","filing":"0001209191-23-002439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123002439/doc4.xml","form_type":"4"}},{"id":2060385,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units (RSUs)","published_at":"2023-01-06T17:54:54.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":18397,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU/PSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vest 1/3rd annually on each anniversary of January 5, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vest 1/3rd annually on each anniversary of January 5, 2023."}],"balance_after":18397,"derivative":{"underlying":"Ordinary Shares","underlying_shares":18397},"source":{"system":"sec-edgar","filing":"0001209191-23-002439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123002439/doc4.xml","form_type":"4"}},{"id":2060384,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-06T17:54:54.000Z","date":"2023-01-06","kind":"sale","acquired":false,"shares":5187,"price":113.29,"value":587635.23,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held in the Jeffrey W. Sherman Living Trust."}],"balance_after":49314,"source":{"system":"sec-edgar","filing":"0001209191-23-002439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123002439/doc4.xml","form_type":"4"}},{"id":2060383,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-06T17:54:54.000Z","date":"2023-01-05","kind":"tax_withholding","acquired":false,"shares":22655,"price":113.24,"value":2565452.2,"ownership":{"direct":true},"balance_after":42907,"source":{"system":"sec-edgar","filing":"0001209191-23-002439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123002439/doc4.xml","form_type":"4"}},{"id":2060382,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-06T17:54:54.000Z","date":"2023-01-05","kind":"exercise","acquired":true,"shares":51132,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU/PSU represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":65562,"source":{"system":"sec-edgar","filing":"0001209191-23-002439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123002439/doc4.xml","form_type":"4"}},{"id":2067400,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units (PSUs)","published_at":"2023-01-04T16:27:11.000Z","date":"2023-01-01","kind":"exercise","acquired":false,"shares":21772,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each PSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares subject to the PSUs vested on January 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The ordinary shares subject to the PSUs vested on January 1, 2023."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":21772},"source":{"system":"sec-edgar","filing":"0001209191-23-000939","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123000939/doc4.xml","form_type":"4"}},{"id":2067399,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-04T16:27:11.000Z","date":"2023-01-01","kind":"tax_withholding","acquired":false,"shares":9717,"price":113.8,"value":1105794.6,"ownership":{"direct":true},"balance_after":14430,"source":{"system":"sec-edgar","filing":"0001209191-23-000939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123000939/doc4.xml","form_type":"4"}},{"id":2067398,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-04T16:27:11.000Z","date":"2023-01-01","kind":"exercise","acquired":true,"shares":21772,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each PSU represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":24147,"source":{"system":"sec-edgar","filing":"0001209191-23-000939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123000939/doc4.xml","form_type":"4"}},{"id":2074938,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units (PSUs)","published_at":"2022-12-29T16:31:20.000Z","date":"2022-12-27","kind":"grant","acquired":true,"shares":13972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each PSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On January 4, 2021, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On December 27, 2022, such performance criteria were met.  Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2023 and the remaining one-third of the ordinary shares vest on January 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 4, 2021, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On December 27, 2022, such performance criteria were met.  Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2023 and the remaining one-third of the ordinary shares vest on January 5, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On January 4, 2021, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On December 27, 2022, such performance criteria were met.  Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2023 and the remaining one-third of the ordinary shares vest on January 5, 2024."}],"balance_after":13972,"derivative":{"underlying":"Ordinary Shares","underlying_shares":13972},"source":{"system":"sec-edgar","filing":"0001209191-22-062917","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122062917/doc4.xml","form_type":"4"}},{"id":2074937,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance Restricted Stock Units (PSUs)","published_at":"2022-12-29T16:31:20.000Z","date":"2022-12-27","kind":"grant","acquired":true,"shares":21772,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each PSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On December 27, 2022, such performance criteria were met.  The ordinary shares subject to the PSUs vest on January 1, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On December 27, 2022, such performance criteria were met.  The ordinary shares subject to the PSUs vest on January 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On December 27, 2022, such performance criteria were met.  The ordinary shares subject to the PSUs vest on January 1, 2023."}],"balance_after":21772,"derivative":{"underlying":"Ordinary Shares","underlying_shares":21772},"source":{"system":"sec-edgar","filing":"0001209191-22-062917","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122062917/doc4.xml","form_type":"4"}},{"id":2087940,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-12-13T16:12:39.000Z","date":"2022-12-12","kind":"sale","acquired":false,"shares":21378,"price":111.4456,"value":2382484.0368,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.20 to $111.74 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held in the name of the Jeffrey W. Sherman 2020 Gift Trust, of which the reporting person's spouse is the Trustee."}],"balance_after":84430,"source":{"system":"sec-edgar","filing":"0001209191-22-060901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122060901/doc4.xml","form_type":"4"}},{"id":2087939,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-12-13T16:12:39.000Z","date":"2022-12-12","kind":"sale","acquired":false,"shares":6974,"price":111.4436,"value":777207.6664,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.20 to $111.71 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in the Jeffrey W. Sherman Living Trust."}],"balance_after":54501,"source":{"system":"sec-edgar","filing":"0001209191-22-060901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122060901/doc4.xml","form_type":"4"}},{"id":2087938,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-12-13T16:12:39.000Z","date":"2022-05-27","kind":"gift","acquired":true,"shares":8531,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in the Jeffrey W. Sherman Living Trust."}],"balance_after":61475,"source":{"system":"sec-edgar","filing":"0001209191-22-060901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122060901/doc4.xml","form_type":"4"}},{"id":2087937,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-12-13T16:12:39.000Z","date":"2022-05-27","kind":"gift","acquired":false,"shares":8531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 277 ordinary shares of the Issuer acquired by the reporting person on June 1, 2022 pursuant to an employee stock purchase program."}],"balance_after":2375,"source":{"system":"sec-edgar","filing":"0001209191-22-060901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122060901/doc4.xml","form_type":"4"}},{"id":2237453,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T21:15:32.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options will vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders."}],"balance_after":25000,"derivative":{"exercise_price":2.1,"exercise_date":"2022-06-08","expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001867096-22-000095","document":"wf-form4_165480931886352.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000186709622000095/wf-form4_165480931886352.xml","form_type":"4"}},{"id":2237452,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-09T21:15:32.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders."}],"balance_after":65378,"source":{"system":"sec-edgar","filing":"0001867096-22-000095","document":"wf-form4_165480931886352.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000186709622000095/wf-form4_165480931886352.xml","form_type":"4"}},{"id":2300237,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-04-08T16:07:51.000Z","date":"2022-04-06","kind":"sale","acquired":false,"shares":42009,"price":110.021,"value":4621872.189,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":10629,"source":{"system":"sec-edgar","filing":"0001209191-22-023841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122023841/doc4.xml","form_type":"4"}},{"id":2323108,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-21T16:25:25.000Z","date":"2022-03-18","kind":"exercise","acquired":false,"shares":8531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":164469,"derivative":{"exercise_price":22.14,"expiration_date":"2025-03-23","underlying":"Ordinary Shares","underlying_shares":8531},"source":{"system":"sec-edgar","filing":"0001209191-22-020259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122020259/doc4.xml","form_type":"4"}},{"id":2323107,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-21T16:25:25.000Z","date":"2022-03-18","kind":"exercise","acquired":true,"shares":8531,"price":22.14,"value":188876.34,"ownership":{"direct":true},"balance_after":52638,"source":{"system":"sec-edgar","filing":"0001209191-22-020259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122020259/doc4.xml","form_type":"4"}},{"id":2323106,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-21T16:25:25.000Z","date":"2022-03-10","kind":"gift","acquired":true,"shares":8169,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held in the Jeffrey W. Sherman Living Trust."}],"balance_after":52944,"source":{"system":"sec-edgar","filing":"0001209191-22-020259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122020259/doc4.xml","form_type":"4"}},{"id":2323105,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-21T16:25:25.000Z","date":"2022-03-10","kind":"gift","acquired":false,"shares":8169,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":44107,"source":{"system":"sec-edgar","filing":"0001209191-22-020259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122020259/doc4.xml","form_type":"4"}},{"id":2323104,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-21T16:25:25.000Z","date":"2021-06-11","kind":"gift","acquired":true,"shares":5287,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":52276,"source":{"system":"sec-edgar","filing":"0001209191-22-020259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122020259/doc4.xml","form_type":"4"}},{"id":2323103,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-21T16:25:25.000Z","date":"2021-06-11","kind":"gift","acquired":false,"shares":5287,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held in the Jeffrey W. Sherman Living Trust."}],"balance_after":44775,"source":{"system":"sec-edgar","filing":"0001209191-22-020259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122020259/doc4.xml","form_type":"4"}},{"id":2323102,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-21T16:25:25.000Z","date":"2021-05-25","kind":"gift","acquired":true,"shares":12304,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held in the Jeffrey W. Sherman Living Trust."}],"balance_after":50062,"source":{"system":"sec-edgar","filing":"0001209191-22-020259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122020259/doc4.xml","form_type":"4"}},{"id":2323101,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-21T16:25:25.000Z","date":"2021-05-25","kind":"gift","acquired":false,"shares":12304,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":46989,"source":{"system":"sec-edgar","filing":"0001209191-22-020259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122020259/doc4.xml","form_type":"4"}},{"id":2427767,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units (RSUs)","published_at":"2022-01-24T17:05:28.000Z","date":"2022-01-21","kind":"exercise","acquired":false,"shares":5354,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":0,"derivative":{"exercise_date":"2022-01-21","expiration_date":"2022-01-21","underlying":"Ordinary Shares","underlying_shares":5354},"source":{"system":"sec-edgar","filing":"0001209191-22-004632","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122004632/doc4.xml","form_type":"4"}},{"id":2427766,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-24T17:05:28.000Z","date":"2022-01-21","kind":"tax_withholding","acquired":false,"shares":2372,"price":86.42,"value":204988.24,"ownership":{"direct":true},"balance_after":59293,"source":{"system":"sec-edgar","filing":"0001209191-22-004632","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122004632/doc4.xml","form_type":"4"}},{"id":2427765,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-24T17:05:28.000Z","date":"2022-01-21","kind":"exercise","acquired":true,"shares":5354,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":61665,"source":{"system":"sec-edgar","filing":"0001209191-22-004632","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122004632/doc4.xml","form_type":"4"}},{"id":2441435,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units (RSU)","published_at":"2022-01-06T20:57:04.000Z","date":"2022-01-05","kind":"exercise","acquired":false,"shares":9314,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2021."}],"balance_after":18628,"derivative":{"underlying":"Ordinary Shares","underlying_shares":9314},"source":{"system":"sec-edgar","filing":"0001209191-22-002285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122002285/doc4.xml","form_type":"4"}},{"id":2441434,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units (RSU)","published_at":"2022-01-06T20:57:04.000Z","date":"2022-01-05","kind":"exercise","acquired":false,"shares":9678,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Two-thirds of the ordinary shares subject to the RSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Two-thirds of the ordinary shares subject to the RSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023."}],"balance_after":4834,"derivative":{"underlying":"Ordinary Shares","underlying_shares":9678},"source":{"system":"sec-edgar","filing":"0001209191-22-002285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122002285/doc4.xml","form_type":"4"}},{"id":2441433,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units (RSU)","published_at":"2022-01-06T20:57:04.000Z","date":"2022-01-05","kind":"exercise","acquired":false,"shares":9222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"50% of the shares subject to the RSU's vested on 1/5/2022, and the remaining shares vest on 1/5/2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"50% of the shares subject to the RSU's vested on 1/5/2022, and the remaining shares vest on 1/5/2023."}],"balance_after":9223,"derivative":{"underlying":"Ordinary Shares","underlying_shares":9222},"source":{"system":"sec-edgar","filing":"0001209191-22-002285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122002285/doc4.xml","form_type":"4"}},{"id":2441432,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units (RSU)","published_at":"2022-01-06T20:57:04.000Z","date":"2022-01-05","kind":"exercise","acquired":false,"shares":12095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2020."}],"balance_after":12095,"derivative":{"underlying":"Ordinary Shares","underlying_shares":12095},"source":{"system":"sec-edgar","filing":"0001209191-22-002285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122002285/doc4.xml","form_type":"4"}},{"id":2441431,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units (RSU)","published_at":"2022-01-06T20:57:04.000Z","date":"2022-01-05","kind":"exercise","acquired":false,"shares":12261,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2019."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":12261},"source":{"system":"sec-edgar","filing":"0001209191-22-002285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122002285/doc4.xml","form_type":"4"}},{"id":2441430,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Restricted Stock Units (RSU)","published_at":"2022-01-06T20:57:04.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":19044,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2022."}],"balance_after":19044,"derivative":{"underlying":"Ordinary Shares","underlying_shares":19044},"source":{"system":"sec-edgar","filing":"0001209191-22-002285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122002285/doc4.xml","form_type":"4"}},{"id":2441429,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-06T20:57:04.000Z","date":"2022-01-05","kind":"tax_withholding","acquired":false,"shares":37675,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":56311,"source":{"system":"sec-edgar","filing":"0001209191-22-002285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122002285/doc4.xml","form_type":"4"}},{"id":2441428,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-06T20:57:04.000Z","date":"2022-01-05","kind":"grant","acquired":true,"shares":32301,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 5, 2022, the PSUs vested as to the number of shares reported above."}],"balance_after":93986,"source":{"system":"sec-edgar","filing":"0001209191-22-002285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122002285/doc4.xml","form_type":"4"}},{"id":2441427,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-06T20:57:04.000Z","date":"2022-01-05","kind":"exercise","acquired":true,"shares":52570,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":61685,"source":{"system":"sec-edgar","filing":"0001209191-22-002285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122002285/doc4.xml","form_type":"4"}},{"id":2441426,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-06T20:57:04.000Z","date":"2021-12-13","kind":"gift","acquired":false,"shares":50,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held in the Jeffrey W. Sherman Living Trust."}],"balance_after":37758,"source":{"system":"sec-edgar","filing":"0001209191-22-002285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122002285/doc4.xml","form_type":"4"}},{"id":2441425,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-06T20:57:04.000Z","date":"2021-11-08","kind":"gift","acquired":true,"shares":10729,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held in the Jeffrey W. Sherman Living Trust."}],"balance_after":37808,"source":{"system":"sec-edgar","filing":"0001209191-22-002285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122002285/doc4.xml","form_type":"4"}},{"id":2441424,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-06T20:57:04.000Z","date":"2021-11-08","kind":"gift","acquired":false,"shares":10729,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9115,"source":{"system":"sec-edgar","filing":"0001209191-22-002285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122002285/doc4.xml","form_type":"4"}},{"id":2531795,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-29T16:55:28.000Z","date":"2021-10-27","kind":"exercise","acquired":false,"shares":10729,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.61,"expiration_date":"2024-01-02","underlying":"Ordinary Shares","underlying_shares":10729},"source":{"system":"sec-edgar","filing":"0001209191-21-062085","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919121062085/doc4.xml","form_type":"4"}},{"id":2531794,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2021-10-29T16:55:28.000Z","date":"2021-10-27","kind":"exercise","acquired":true,"shares":10729,"price":7.61,"value":81647.69,"ownership":{"direct":true},"balance_after":19844,"source":{"system":"sec-edgar","filing":"0001209191-21-062085","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919121062085/doc4.xml","form_type":"4"}},{"id":2547003,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-06T23:41:29.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":140000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001179110-21-009279","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000117911021009279/edgar.xml","form_type":"4"}},{"id":2547002,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-10-06T23:41:29.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":64258,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. (\"HoldCo\") pursuant to the Transaction Agreement (the \"Agreement\"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a \"CVR\") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. (\"HoldCo\") pursuant to the Transaction Agreement (the \"Agreement\"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a \"CVR\") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-21-009279","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000117911021009279/edgar.xml","form_type":"4"}},{"id":2548399,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:41:43.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":11228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders."}],"balance_after":11228,"derivative":{"exercise_price":3.9,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":11228},"source":{"system":"sec-edgar","filing":"0000899243-21-039322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000089924321039322/doc4.xml","form_type":"4"}},{"id":2548398,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:41:43.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":11228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested as of the date hereof."}],"balance_after":11228,"derivative":{"exercise_price":4.68,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":11228},"source":{"system":"sec-edgar","filing":"0000899243-21-039322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000089924321039322/doc4.xml","form_type":"4"}},{"id":2548397,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:41:43.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested as of the date hereof."}],"balance_after":20000,"derivative":{"exercise_price":10,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-21-039322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000089924321039322/doc4.xml","form_type":"4"}},{"id":2548396,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:41:43.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":19650,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested as of the date hereof."}],"balance_after":19650,"derivative":{"exercise_price":12.5,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":19650},"source":{"system":"sec-edgar","filing":"0000899243-21-039322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000089924321039322/doc4.xml","form_type":"4"}},{"id":2548395,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:41:43.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":31360,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested as of the date hereof."}],"balance_after":31360,"derivative":{"exercise_price":9.89,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":31360},"source":{"system":"sec-edgar","filing":"0000899243-21-039322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000089924321039322/doc4.xml","form_type":"4"}},{"id":2548394,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:41:43.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":31360,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested as of the date hereof."}],"balance_after":31360,"derivative":{"exercise_price":5.62,"expiration_date":"2027-05-11","underlying":"Common Stock","underlying_shares":31360},"source":{"system":"sec-edgar","filing":"0000899243-21-039322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000089924321039322/doc4.xml","form_type":"4"}},{"id":2548393,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:41:43.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":47040,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the \"Strongbridge Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested as of the date hereof."}],"balance_after":47040,"derivative":{"exercise_price":6.66,"expiration_date":"2026-10-01","underlying":"Common Stock","underlying_shares":47040},"source":{"system":"sec-edgar","filing":"0000899243-21-039322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000089924321039322/doc4.xml","form_type":"4"}},{"id":2548392,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-05T23:41:43.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":50378,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\"). At the effective time of the Merger (the \"Merger Effective Time\"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\"). At the effective time of the Merger (the \"Merger Effective Time\"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis."}],"balance_after":50378,"source":{"system":"sec-edgar","filing":"0000899243-21-039322","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000089924321039322/doc4.xml","form_type":"4"}},{"id":2548391,"issuer":{"id":131608,"kind":"organization","name":"Strongbridge Biopharma plc","symbol":"SBBP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-10-05T23:23:02.000Z","date":"2021-10-01","kind":"tax_withholding","acquired":false,"shares":17763,"price":2.06,"value":36591.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units."}],"balance_after":64258,"source":{"system":"sec-edgar","filing":"0001179110-21-009221","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000117911021009221/edgar.xml","form_type":"4"}},{"id":2548390,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T21:38:05.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":11228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders."}],"balance_after":0,"derivative":{"exercise_price":3.9,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":11228},"source":{"system":"sec-edgar","filing":"0000899243-21-039259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000089924321039259/doc4.xml","form_type":"4"}},{"id":2548389,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T21:38:05.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":11228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":4.68,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":11228},"source":{"system":"sec-edgar","filing":"0000899243-21-039259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000089924321039259/doc4.xml","form_type":"4"}},{"id":2548388,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T21:38:05.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":10,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-21-039259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000089924321039259/doc4.xml","form_type":"4"}},{"id":2548387,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T21:38:05.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":19650,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":12.5,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":19650},"source":{"system":"sec-edgar","filing":"0000899243-21-039259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230482/000089924321039259/doc4.xml","form_type":"4"}},{"id":2560868,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-23T17:00:33.000Z","date":"2021-09-21","kind":"exercise","acquired":false,"shares":46271,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."}],"balance_after":10729,"derivative":{"exercise_price":7.61,"expiration_date":"2024-01-02","underlying":"Ordinary Shares","underlying_shares":46271},"source":{"system":"sec-edgar","filing":"0001209191-21-057450","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919121057450/doc4.xml","form_type":"4"}},{"id":2560867,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":45619,"kind":"person","name":"SHERMAN JEFFREY W","position":1,"cik":"0001230482","reported_name":"SHERMAN JEFFREY W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2021-09-23T17:00:33.000Z","date":"2021-09-21","kind":"sale","acquired":false,"shares":46271,"price":110,"value":5089810.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2021."}],"balance_after":9115,"source":{"system":"sec-edgar","filing":"0001209191-21-057450","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919121057450/doc4.xml","form_type":"4"}}],"next_cursor":"2021-09-23T17:00:33.000000Z,2560867"}